Fitch Ratings has lowered its outlook on Jubilant Pharma Ltd's (JPL's) long-term Issuer Default Rating (IDR) from “stable” to “negative” on expectation of a deterioration in the company's profitability. This is likely to see financial leverage of Jubilant Pharma surge to above the negative rating sensitivity level in the financial year ending March 2023 (FY23).
The agency affirmed the IDR at 'BB' for the Singapore-based company.
Jubilant Pharma's profitability should stabilise in FY24, which would help leverage return to below the negative rating sensitivity level. Nevertheless, JPL's weak headroom underscores the downside risks from operational underperformance or investments that were more aggressive than Fitch expected, Fitch said in a statement.
JPL's limited dependence on generic formulations and favourable market position in speciality pharmaceutical-focused segments underpins its credit profile. This was despite its small size and the high degree of regulatory risk arising from limited production-facility diversification.
Lower profitability
Fitch estimates the pharma company’s EBITDA to drop significantly in FY23, due to lower volume and narrowing of the margin to 11 per cent (FY22 estimated: 14 per cent). A slow volume recovery at JPL's high-margin radio-pharma business will coincide with higher R&D spending and the tapering of the Covid-19 pandemic-related uplift in contract manufacturing of sterile products (CMO) and generic dosage segments, Fitch said.
JPL is shifting its active pharmaceutical ingredients (API) business to its parent, Jubilant Pharmova Limited (JPHL). The expected pricing pressure would weigh on profitability in the generic segment, despite the normalisation of one-off factors in 2HFY22. The estimates do not factor in yet-to-be approved products and hence remain more conservative than JPL's FY24 expectations, it added.
Weak leverage headroom
JPL's financial leverage, measured by consolidated net debt/EBITDA, is expected to rise to 3.9x in FY23, from 1.8x in FY21. This is above the 3.0x level where the rating agency would consider negative rating action. Pre-Research & Development EBITDA in FY24 is likely to remain above our FY22 estimate, but elevated R&D spending along with expansion capex will narrow leverage headroom.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU